No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Asset Management
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
www.bbbiotech.ch/ch-en/privateNo one on the platform currently holds BION.SW.
No tracked institution reports a position in BION.SW as of their last filing.
No one on the platform has traded BION.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 21.9% | — | — | — | ||
| Rev. Growth % | -31.2% | -35.7% | ||||
| Profit Margin % | 752.7% | -1906936.6% | -953418.4% | |||
| Free Cash Flow Margin % | 402.5% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.3B | +107.3% | $2.58 | $2.58–$2.58 | — | 1 |
| 2027 | $1.3B | +0.0% | $2.02 | $2.02–$2.02 | — | 1 |
| 2028 | $1.3B | +0.0% | $1.87 | $-0.24–$3.98 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BION.SWBB Biotech AG | $52.40 | -0.19% | $2.9B | — |
| ADXN.SWAddex Therapeutics Ltd | $0.02 | +3.39% | $4M | — |
| BSLN.SWBasilea Pharmaceutica AG | $66.10 | -0.90% | $818M | — |
| EVE.SWEvoNext Holdings S.A. | $2.05 | -8.89% | $15M | — |
| IDIA.SWIdorsia Ltd | $5.00 | -0.04% | $1.3B | — |
| KURN.SWKuros Biosciences AG | $17.84 | -2.09% | $704M | — |
| MOLN.SWMolecular Partners AG | $3.27 | -1.80% | $123M | — |
Source: Financial Modeling Prep · peers by sector/industry